Search results for "Drug treatment"

showing 10 items of 75 documents

Giant hepatic hydatid cyst as a cause of small bowel obstruction.

2006

Today, giant hydatid cysts are fairly rare even in endemic areas. We describe a case of an extremely large hydatid cyst of the liver that was causing massive compression of the neighboring organs, giving rise to a subocclusive syndrome of the intestine. After considering the various approaches available for the treatment of this disease, it was decided that radical surgery was still the best therapeutic choice, especially when extremely large cysts are involved. In particular, in clinical situations where it is difficult to perform radical surgical procedures, less aggressive surgery followed by drug treatment should be the treatment of choice.

Malemedicine.medical_specialtyEchinococcosis Hepaticalanine aminotransferase aspartate aminotransferase contrast mediumoral contraceptive agentHelminthiasisAntiprotozoal AgentsHydatid cystHepatic ComplicationAlbendazoleAggressive surgeryDrug treatmentparasitic diseasesIntestine SmallmedicineHumansRadical surgeryAgedbusiness.industryGeneral Medicinemedicine.diseaseEchinococcosisSurgeryBowel obstructionSettore MED/18 - Chirurgia GeneraleDrug Therapy CombinationbusinessTomography X-Ray ComputedIntestinal Obstruction
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.

2020

ABSTRACT Background Little evidence on COVID‐19 in people living with HIV (PLWH) is currently available. Material and Methods We reported clinical and viro‐immunological data of all HIV‐positive patients admitted to our centre with COVID‐19 from March 1 to May 12,2020. Results Overall, five patients were included: all were virologically‐suppressed on antiretroviral therapy and CD4+ count was >350 cell/mm3 in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. SARS‐CoV‐2‐RNA was never detected from nasopharyngeal swabs in two patients, whereas, in the others, viral clearance occurred within a maximum of 43 days. IgG prod…

Malemedicine.medical_treatmentHIV InfectionsAntibodies ViralSeverity of Illness IndexImmunoglobulin GPiperazinesimmune responseSARS‐CoV‐20302 clinical medicine030212 general & internal medicinebiologyCoinfectionImmunosuppressionMiddle AgedInfectious DiseasesAnti-Retroviral AgentsCytokinesRNA ViralReverse Transcriptase Inhibitors030211 gastroenterology & hepatologyFemaleAntibodyHeterocyclic Compounds 3-RingRiskPyridonesShort CommunicationShort CommunicationsTransgender PersonsProinflammatory cytokine03 medical and health sciencesImmune systemCOVID‐19VirologySeverity of illnessOxazinesmedicineHumansHIV Integrase InhibitorsTenofovirbusiness.industrySARS-CoV-2medicine.diseaseHIV infectionVirologyAntibodies NeutralizingCD4 Lymphocyte CountImmunity HumoralCOVID-19 Drug TreatmentPneumoniaRespiratory failureImmunologybiology.proteinbusinessJournal of medical virology
researchProduct

Cardiac Injury in COVID-19–Echoing Prognostication∗

2020

Background Myocardial injury is frequent among patients hospitalized with coronavirus disease-2019 (COVID-19) and is associated with a poor prognosis. However, the mechanisms of myocardial injury remain unclear and prior studies have not reported cardiovascular imaging data. Objectives This study sought to characterize the echocardiographic abnormalities associated with myocardial injury and their prognostic impact in patients with COVID-19. Methods We conducted an international, multicenter cohort study including 7 hospitals in New York City and Milan of hospitalized patients with laboratory-confirmed COVID-19 who had undergone transthoracic echocardiographic (TTE) and electrocardiographic…

Malemyocaardial injuryCoronary AngiographyElectrocardiographyPandemicVentricular Dysfunctionechocardiographymyocardial injuryOriginal Investigationechocardiography; inflammation; myocaardial injury; SARS-CoV-2; troponin; COVID-19COVID-19 coronavirus disease-2019biologyViral EpidemiologytroponinHeartMiddle AgedRV right ventriclemyocardial infarctionItalyTTE transthoracic echocardiographyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsEditorial Comment2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAKI acute kidney injuryECG electrocardiographyBetacoronavirusmedicineHumansPandemicsARDS acute respiratory distress syndromeIQR interquartile rangeAgedRetrospective Studiesbusiness.industrySARS-CoV-2MyocardiumCOVID-19medicine.diseasebiology.organism_classificationVirologyCOVID-19 Drug TreatmentCI confidence intervalOR odds ratioPneumoniaLV left ventricleinflammationACS acute coronary syndromeNew York CitybusinessCoronavirus InfectionsBetacoronavirusBiomarkersJournal of the American College of Cardiology
researchProduct

Oral antiseptics against coronavirus: in-vitro and clinical evidence

2021

Background Angiotensin converting enzyme II (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection. ACE2 receptors are highly expressed in the oral cavity so this may be a potential high-risk route for SARS-CoV-2 infection. Furthermore, the virus can be detected in saliva, even before COVID-19 symptoms appear, with the consequent high risk of virus transmission in asymptomatic/pre-symptomatic patients. Reducing oral viral load could lead to a lower risk of transmission via salivary droplets or aerosols and therefore contribute to the control of the pandemic. Aim To evaluate the available evidence testing the in vitro…

Microbiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtySalivaCoronavirus disease 2019 (COVID-19)coronavirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesMouthwashesCetylpyridiniumReviewmedicine.disease_causeLower riskViruslaw.inventionoral antisepticsRandomized controlled triallawInternal medicinemedicineHumansSalivaLetter to the EditorPandemicsPovidone-IodineCoronavirusMouthSARS-CoV-2Transmission (medicine)business.industryCOVID-19Hydrogen PeroxideGeneral MedicineViral LoadVirologyIn vitroCOVID-19 Drug TreatmentCoronavirusoral rinseInfectious DiseasesSystematic reviewClinical evidenceAnti-Infective Agents LocalCoronavirus InfectionsbusinessViral loadJournal of Hospital Infection
researchProduct

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection

2020

COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs in synergy structure- and ligand-based studies by means of the molecular docking and descriptor-based protocol. The proposed in silico findings identified new potential SARS CoV-2 main protease (MPRO) inhibitors that fit in the catalytic binding site of SARS CoV-2 MPRO. Several sel…

Models Molecular0301 basic medicineAgingmedicine.medical_treatmentcoronaviruslcsh:QR1-502Viral Nonstructural Proteinsmedicine.disease_causelcsh:Microbiology0302 clinical medicineSettore BIO/10 - BiochimicaCoronavirus 3C ProteasesCoronavirusvirus diseasesLopinavirHypothesisMolecular Docking SimulationCysteine EndopeptidasesDrug repositioningInfectious Diseases030220 oncology & carcinogenesisCoronavirus InfectionsOxidation-Reductionmedicine.drugDNA damageIn silicoPneumonia ViralBiologyAntiviral AgentsHIV-proteaseBetacoronavirus03 medical and health sciencesSARS-CoV-2 main proteaseVirologymedicineHumansComputer SimulationProtease InhibitorsPandemicsBinding SitesProteaseSARS-CoV-2Drug RepositioningCOVID-19HIV Protease InhibitorsDRUDIT web servicemolecular dockingNADbiology.organism_classificationVirologySettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug Treatmentcoronaviru030104 developmental biologyNADHRitonavirBetacoronavirusDNA Damage
researchProduct

The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations

2020

Graphical abstract The inorganic physiological polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. This discovery proposes polyphosphate as a new member of the host's antiviral innate immune defense.

Models Molecular0301 basic medicineAntiviral AgentsBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePolyphosphatesPolyphosphateHuman Umbilical Vein Endothelial Cellsotorhinolaryngologic diseasesHumansPlateletReceptorneoplasmsPharmacologychemistry.chemical_classificationBinding assayInnate immune systemSARS-CoV-2 spike S-proteinLigand binding assayPolyphosphateCOVID-19pathological conditions signs and symptomsdigestive system diseasesCOVID-19 Drug TreatmentAmino acidsurgical procedures operative030104 developmental biologyEnzymechemistryBiochemistry030220 oncology & carcinogenesisSpike Glycoprotein CoronavirusNanoparticlesAlkaline phosphataseAngiotensin-Converting Enzyme 2Protein BindingReceptors CoronavirusBiochemical Pharmacology
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

BANΔIT: B’‐factor Analysis for Drug Design and Structural Biology

2020

The analysis of B‐factor profiles from X‐ray protein structures can be utilized for structure‐based drug design since protein mobility changes have been associated with the quality of protein‐ligand interactions. With the BANΔIT (B’‐factor analysis and ΔB’ interpretation toolkit), we have developed a JavaScript‐based browser application that provides a graphical user interface for the normalization and analysis of B’‐factor profiles. To emphasize the usability for rational drug design applications, we have analyzed a selection of crystallographic protein‐ligand complexes and have given exemplary conclusions for further drug optimization including the development of a B’‐factor‐supported pha…

Normalization (statistics)Source codeComputer scienceBioinformaticsmedia_common.quotation_subjectDrug designB-factorMolecular modelingWeb BrowserJavaScriptcomputer.software_genre01 natural sciences03 medical and health sciencesStructural BiologyFactor (programming language)Drug DiscoveryApplication NoteHumansProtein flexibilityProtease Inhibitors030304 developmental biologycomputer.programming_languagemedia_commonGraphical user interface0303 health sciencesbusiness.industrySARS-CoV-2Organic ChemistryComputational BiologyUsabilityAdenosine Monophosphate0104 chemical sciencesComputer Science ApplicationsCOVID-19 Drug Treatment010404 medicinal & biomolecular chemistryDrug DesignMolecular MedicineData miningPharmacophorebusinesscomputerMolecular Informatics
researchProduct

Isolated Lung Perfusion as an Adjuvant Treatment of Colorectal Cancer Lung Metastases: A Preclinical Study in a Pig Model

2012

BackgroundThe lung is a frequent site of colorectal cancer (CRC) metastases. After surgical resection, lung metastases recurrences have been related to the presence of micrometastases, potentially accessible to a high dose chemotherapy administered via adjuvant isolated lung perfusion (ILP). We sought to determine in vitro the most efficient drug when administered to CRC cell lines during a short exposure and in vivo its immediate and delayed tolerance when administered via ILP.MethodsFirst, efficacy of various cytotoxic molecules against a panel of human CRC cell lines was tested in vitro using cytotoxic assay after a 30-minute exposure. Then, early (operative) and delayed (1 month) tolera…

OncologyCardiothoracic SurgeryPathologyLung NeoplasmsSwineColorectal cancerIsolated lung perfusionmedicine.medical_treatmentCancer TreatmentCardiovascularDeoxycytidineMetastasischemistry.chemical_compoundDrug DistributionMultidisciplinaryQRThoracic SurgeryPerfusionTreatment OutcomeSurgical Oncologymedicine.anatomical_structureOncologyChemotherapy AdjuvantMedicineDeoxycytidineColorectal NeoplasmsAdjuvantResearch ArticleDrugs and Devicesmedicine.medical_specialtyScienceAntineoplastic AgentsIn vivoCell Line TumorInternal medicinemedicineAnimalsHumansPulmonary Vascular DiseasesPharmacokineticsAnalysis of VarianceChemotherapyLungDose-Response Relationship Drugbusiness.industryHemodynamicsChemotherapy and Drug Treatmentmedicine.diseaseGemcitabineDrug LiberationchemistryVasoconstrictionSurgerybusinessPLoS ONE
researchProduct